ATP13A2 Antikörper (PE)
Kurzübersicht für ATP13A2 Antikörper (PE) (ABIN1427815)
Target
Alle ATP13A2 Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Aufreinigung
- Purified by Protein A.
-
Immunogen
- KLH conjugated synthetic peptide derived from human ATP13A2
-
Isotyp
- IgG
-
-
-
-
Kommentare
-
Exitation/Emission: 480,565nm/578nm
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Liquid
-
Konzentration
- 1 μg/μL
-
Buffer
- Aqueous buffered solution containing 100 μg/mL BSA, 50 % glycerol and 0.09 % sodium azide.
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at 4°C
-
Haltbarkeit
- 12 months
-
-
- ATP13A2 (ATPase Type 13A2 (ATP13A2))
-
Andere Bezeichnung
- Park9/Atp13a2
-
Hintergrund
-
ATP13A2 is a 1,180 amino acid multi-pass membrane protein that belongs to the P5 subfamily of ATPases which play an important role in the transportation of inorganic cations. Expressed as multiple alternative spliced isoforms, ATP13A2 functions to catalyze the conversion of ATP to ADP and a free phosphate, thereby participating in the active transport of ions across cellular membranes. Defects in the gene encoding ATP13A2 are the cause of Kufor-Rakeb syndrome (KRS), a rare hereditary type of Parkinson’s disease that exhibits juvenile onset and is characterized by neurodegeneration and dementia. The ATP13A2 gene maps to human chromosome 1, which spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8 % of the human genome.
Subcellular location: Extracellular
Synonyms: AT132_HUMAN, Atp13a2, ATPase type 13A2, CLN12, HSA9947, KRPPD, PARK9, Probable cation transporting ATPase 13A2, Probable cation-transporting ATPase 13A2, Putative ATPase, RP1-37C10.4. -
Pathways
- Ribonucleoside Biosynthetic Process
Target
-